Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Personalized medicine stories

Oct 29, 2026

iDIET shows improved outcomes for eosinophilic esophagitis in randomized trial

A novel allergen-specific, immune signature-directed diet (iDIET) led to significant improvements in histologic and endoscopic responses in patients with eosinophilic esophagitis compared with a sham elimination diet, according to results from a small randomized study presented in Nashville, Tennessee.

Oct 29, 2026·1 source
00
Oct 28, 2026

FDA releases guidance for individualized gene editing therapies

The FDA published new guidance establishing an approval framework for personalized gene editing treatments that could benefit different patient subsets with the same disease, creating a 'plug and play' pathway to accelerate individualized therapies.

Oct 28, 2026·2 sources
00
Oct 27, 2026

GradientScreen lab-on-chip technology predicts childhood leukemia treatment response

Researchers have developed a gradient-driven microfluidic lab-on-chip platform called GradientScreen that can predict which drug combinations will be most effective for treating pediatric acute lymphoblastic leukemia. The technology screens ratiometric drug combinations to enable precision oncology approaches for the disease, which affects more than 3,500 children annually in the U.S.

Oct 27, 2026·3 sources
00
Oct 23, 2026

Diagnostic test could help doctors refine prostate cancer treatment with abiraterone

A novel diagnostic test could enable doctors to identify which prostate cancer patients would benefit from more intensive treatment with drugs like abiraterone, while sparing others from unnecessary side effects. The test aims to address the challenge of tailoring treatment for prostate cancer, which affects over 1 million men worldwide and behaves differently in each patient.

Oct 23, 2026·5 sources
00
Oct 22, 2026

Moderna and Merck melanoma vaccine cuts death or recurrence risk by 42% in phase 3 trial

The mRNA-based personalized cancer vaccine combined with Keytruda reduced the risk of melanoma death or recurrence by 42% in a late-stage trial, though leaked data triggered a sell-off in Moderna shares despite meeting expectations.

Oct 22, 2026·5 sources
00

Study finds most people carry high genetic risk for three common diseases

University of Exeter researchers have characterized the 'average' human genome for the first time, revealing that most people carry high genetic risk for around three of 28 common conditions, including diabetes, cardiovascular disease, and schizophrenia, though this does not mean they are destined to become ill.

Oct 22, 2026·3 sources
00
Oct 19, 2026

Peter Mac scientists develop CRISPR method to target gene fusions in one in five cancers

Scientists at Peter MacCallum Cancer Centre have developed a new CRISPR approach using PspCas13b nuclease to precisely target abnormal gene fusions, which occur in approximately 20% of cancers. The technique targets the unique molecular fingerprint created when two genes fuse together, potentially offering a new personalized treatment strategy.

Oct 19, 2026·1 source
00
Oct 14, 2026

Merck CEO says cancer vaccine with Moderna will become faster to manufacture

Merck CEO Rob Davis said he expects the personalized cancer vaccine being developed with Moderna to have a shortened production timeline from its current six-week manufacturing period. The announcement comes after the companies reported promising late-stage trial results in August for the mRNA vaccine combined with immunotherapy for melanoma.

Oct 14, 2026·4 sources
00
Sep 19, 2026

mRNA cancer vaccines expand beyond melanoma to lung and pancreatic cancer trials

Following the breakthrough success of an mRNA melanoma vaccine, clinical trials are now underway testing similar vaccine technology for lung cancer, pancreatic cancer, and other diseases.

Sep 19, 2026·1 source
00
Aug 24, 2026

Bristol Myers ends blood cancer drug partnership with Cellares

Bristol Myers Squibb terminated its partnership with cell therapy startup Cellares to expand manufacturing of its personalized blood cancer therapy, prompting Cellares to lay off 100 employees.

Aug 24, 2026·2 sources
00
Aug 19, 2026

Moderna and Merck's mRNA cancer vaccine reduces melanoma recurrence in late-stage trial

Moderna and Merck announced positive results from a Phase 3 trial showing their personalized mRNA cancer vaccine, combined with Keytruda, significantly reduced melanoma recurrence and spread. The companies aim to bring the therapy to market in 2027.

Aug 19, 2026·6 sources
00
Aug 11, 2026

French study finds stopping statins at 75 doesn't increase mortality in low-risk patients

A French randomized trial found that discontinuing statins in people aged 75 and older who were taking them for primary prevention showed non-inferiority to continuing the drugs in terms of all-cause mortality over 3 years. The findings support individualized decision-making for statin use in older adults without previous cardiovascular disease.

Aug 11, 2026·2 sources
00
Aug 7, 2026

Growth hormone therapy shows variable effectiveness in helping childhood stem cell transplant survivors achieve normal height

New research on hematopoietic stem cell transplantation (HCT) survivors reveals that while growth hormone therapy can help children who received transplants for life-threatening cancers and disorders grow taller, individual responses to treatment vary significantly.

Aug 7, 2026·1 source
00

Growth hormone therapy shows variable effectiveness in helping childhood stem cell transplant survivors achieve normal height

New research on hematopoietic stem cell transplantation (HCT) survivors reveals that while growth hormone therapy can help children who received transplants for life-threatening cancers and disorders grow taller, individual responses to treatment vary significantly.

Aug 7, 2026·1 source
00

Breast tumor microenvironment cells may predict tamoxifen treatment effectiveness, study finds

Research from Karolinska Institutet published in BMC Medicine reveals that the types of cells surrounding a breast tumor may influence the long-term effectiveness of tamoxifen hormone therapy, potentially helping identify which patients benefit most from the treatment.

Aug 7, 2026·1 source
00
Aug 4, 2026

Biotech Startup Abandons Plans to Scale Custom CRISPR Therapies

A startup that had promised to commercialize and scale personalized CRISPR gene-editing therapies has abruptly canceled its plans, marking a setback for the custom therapeutics sector.

Aug 4, 2026·1 source
00
Jul 21, 2026

Personalized Antisense Therapy Shows Promise in Treating Rare Genetic Epilepsy in Two Patients

Two patients with SCN2A-related developmental epileptic encephalopathy experienced reductions in seizure frequency after receiving individualized allele-selective antisense oligonucleotides. The treatments were well tolerated, with no ASO-related serious adverse events reported in two parallel single-patient studies published in Nature Medicine.

Jul 21, 2026·1 source
00
Jul 4, 2026

Phase Ib Trial Shows Safety of Personalized Dendritic Cell Vaccine for Newly Diagnosed Glioblastoma

Researchers report safety and preliminary efficacy results from a phase Ib clinical trial testing personalized neoantigen-pulsed autologous dendritic cell vaccination in patients with newly diagnosed glioblastoma, a deadly brain cancer with limited treatment options.

Jul 4, 2026·2 sources
00
Jun 1, 2026

Moderna's personalized mRNA melanoma vaccine cuts cancer recurrence risk by half in five-year trial results

New clinical trial results presented at the American Society of Clinical Oncology show that Moderna's experimental personalized mRNA vaccine, combined with immunotherapy, significantly reduced the risk of deadly melanoma returning after five years. The vaccine is custom-made for each patient based on their specific tumor.

Jun 1, 2026·4 sources
00
May 1, 2026

UK researchers develop tool to identify people at highest risk of obesity-related diseases

British researchers have created a new diagnostic tool designed to identify individuals most at risk of developing obesity-related diseases, which could help target weight-loss medications to those who would benefit most from treatment.

May 1, 2026·1 source
00
Apr 15, 2026

BRCA Gene Mutations Now Linked to Thyroid, Bladder, Skin and Head-Neck Cancers

International research led by RIKEN Center for Integrative Medical Sciences discovered new associations between pathogenic BRCA1 and BRCA2 gene variants and four additional cancer types beyond the previously known breast and ovarian cancers.

Apr 15, 2026·1 source
00

Top claims

  • ▪Patients on the iDIET protocol achieved a 36% endoscopic response rate at week 8 compared to 9% for those on the sham diet in the clinical trial presented by Evan S. Dellon.
  • ▪The initial randomized trial achieved its primary goal of demonstrating the feasibility of implementing the iDIET protocol in a clinical setting.
  • ▪Researchers led by Evan S. Dellon developed iDIET using allergen-specific immune signatures based on food-specific IgG4 in esophageal biopsies and peripheral blood T-cell stimulation across an 18-food panel.

Subtopics

Drug Policy, Pricing & Approval11Drug Approval and Clinical Trials9Cancer & Oncology7Clinical trials7Cancer immunotherapy5MRNA vaccine technology5Vaccines and Immunization Policy5Clinical Genomics & Genetics4Oncology4Cancer treatment3Cancer treatment breakthroughs3Gene therapy3Pharma3Preventive medicine3Vaccine development3Biotechnology2Cancer Types2Clinical evaluation2Clinical Trial Design & Evaluation2Genetic testing2Growth hormone therapy2Hematology & Blood Cancers2Pharmaceutical Industry2Precision medicine2

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories